Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
oncogenic tyrosine kinase
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "oncogenic tyrosine kinase" in MCE Product Catalog:
TM-1 is a potent inhibitor of pyruvate dehydrogenase kinase (PDHK1). TM-1 inhibits PDHK1 and PDHK2 with IC50s of 2.97 μM and 5.2 μM, respectively. TM-1 blocks pyruvate dehydrogenase complex (PDHC) phosphorylation, and inhibits cell proliferation .
SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.
Cat. No.: HY-164482
CAS No.: 2177298-99-4
HG-6-63-01 is a type II RET tyrosine kinase inhibitor (TKI). HG-6-63-01 also inhibits REarranged during Transfection (RET) kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles. HG-6-63-01 impairs phosphorylation and signalling of RET oncogenic mutants. HG-6-63-01 blunts proliferation of RET/C634R and RET/M918T-transformed fibroblasts and of RET mutant thyroid cancer cells, which is promising for research of cancers harboring oncogenic activation of RET .
Cat. No.: HY-121706
CAS No.: 422508-29-0
PU-20F is a Hsp90 inhibitor with an EC50 of 6.8 μM. PU-20F competes with Geldanamycin (HY-15230) for binding to Hsp90 and regulates the function of this molecular chaperone. PU-20F induces the degradation of oncogenic Her2 tyrosine kinase. PU-20F blocks the growth of breast cancer cells. PU-20F can be used in breast cancer-related research .
Cat. No.: HY-184419
YZZ-24 is a highly potent and selective STAT3 inhibitor featuring a Ki of 0.26 μM. YZZ-24 directly binds to STAT3 (STAT3 SH2 domain) and effectively inhibits STAT3 phosphorylation at tyrosine 705 (p-STAT3 Tyr705) and STAT3 phosphorylation at serine 727 (p-STAT3 Ser727), thereby blocking downstream oncogenic signaling and inducing apoptosis, while having minimal impact on upstream kinases. YZZ-24 can be used in colorectal cancer research .
Cat. No.: HY-P992396
Target:
Research Areas:
Cat. No.: HY-P705789
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MET; Soluble MET Variant 13; MET Proto-Oncogene, Receptor tyrosine kinase; Soluble MET Variant 14; Hepatocyte Growth Factor Receptor; Soluble MET Variant 15; DFNB97; Soluble MET Variant 1; RCCP2; Soluble MET Variant 2; HGFR; Soluble MET Variant 3; tyrosine-Protein kinase Met; Soluble MET Variant 5; Scatter Factor Receptor; Soluble MET Variant 6; Proto-Oncogene C-Met; Soluble MET Variant 7; HGF/SF Receptor; Soluble MET Variant 8; HGF Receptor; Soluble MET Variant 9; SF Receptor; Met Proto-Oncogene; Met Proto-Oncogene Variant I; MET Protein; Proto-oncogenic Met Protein; AUTS9; Soluble MET Variant 10; C-Met; Soluble MET Variant 11; DA11; Soluble MET Variant 12
Species:
Human
Source:
sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
